MDF held the first myotonic dystrophy Patient-Focused Drug Development meeting with key senior leadership from the Food and Drug Administration (FDA) as part of the 2016 MDF Annual Conference. We designed the meeting to build on the work MDF has been conducting with the FDA to define and optimize the regulatory pathway for potential DM therapies. The meeting, the first Externally-Led PFDD meeting and the largest PFDD meeting held to date with over 200 attendees in the room and online, is helping change the way the FDA understands DM, the DM community and the approach to regulatory review for DM therapies.
We are the focus of the latest “BioFlash" podcast by the San Francisco Business Times! Check out the interviews with our incredible champions, Erica and Jeremy Kelly (Chairman of the MDF Board), and our CEO, Molly White. We are thrilled by this opportunity to raise awareness of DM in the biotech community. Click here to read the article and listen to the podcast.
The Jensen family hosts an incredible crawfish boil each summer to support Care and a Cure. This year’s boil was bigger than ever with San Diego Harley-Davidson as a partner. To date, this event has raised nearly $100,000! Read more here.
Rare Disease Day on Feb 29th gives us an opportunity to shine a spotlight on DM. MDF has activities planned for the entire month of February. Find out how you can join us in speaking out about DM.
Many MDF community members are aware of an important, multi-year MDF effort -- MDF 3.0: Accelerating Drug Development -- because we published an article on the launch of this initiative in early 2015. Read a full report on the first-year results of MDF 3.0: Accelerating Drug Development, and the initiatives we are pursuing to promote the development of new DM therapies.